Huntington National Bank increased its stake in Edwards Lifesciences Corp (EW) by 5.72% based on its latest 2019Q2 regulatory filing with the SEC. Huntington National Bank bought 16,728 shares as the company’s stock rose 21.36% . The institutional investor held 309,218 shares of the industrial specialties company at the end of 2019Q2, valued at $57.13M, up from 292,490 at the end of the previous reported quarter. Huntington National Bank who had been investing in Edwards Lifesciences Corp for a number of months, seems to be bullish on the $51.28B market cap company. The stock increased 0.52% or $1.28 during the last trading session, reaching $245.84. About 863,489 shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 49.70% since December 4, 2018 and is uptrending. It has outperformed by 49.70% the S&P500.
Huntington National Bank, which manages about $6.21B US Long portfolio, decreased its stake in Ishares (Prn) (EFAV) by 64,503 shares to 56,724 shares, valued at $4.12 million in 2019Q2, according to the filing. It also reduced its holding in Anthem Inc (NYSE:ANTM) by 24,367 shares in the quarter, leaving it with 107,024 shares, and cut its stake in Ishares (Prn) (IJR).
More notable recent Edwards Lifesciences Corporation (NYSE:EW) news were published by: Seekingalpha.com which released: “Comparing ‘FANG’ Stocks With ‘MADGAG’, Also We Closed S&P At 3,120; My Top: 3,150; Hedge – Seeking Alpha” on November 17, 2019, also Finance.Yahoo.com with their article: “A Close Look At Edwards Lifesciences Corporationâ€™s (NYSE:EW) 23% ROCE – Yahoo Finance” published on November 15, 2019, Ocbj.com published: “Drucker: Edwards a Top-Run Company – Orange County Business Journal” on November 22, 2019. More interesting news about Edwards Lifesciences Corporation (NYSE:EW) were released by: Streetinsider.com and their article: “Edwards Lifesciences (EW) PT Raised to $275 at Cowen; ‘Favorable Q4 Setup’ – StreetInsider.com” published on December 03, 2019 as well as Ocbj.com‘s news article titled: “Midday Stock Roundup – Orange County Business Journal” with publication date: November 12, 2019.
Edwards Lifesciences Corporation (NYSE:EW) Ratings Coverage
Among 14 analysts covering Edwards Lifesciences Corporation Common Stock (NYSE:EW), 10 have Buy rating, 1 Sell and 3 Hold. Therefore 71% are positive. Edwards Lifesciences Corporation Common Stock has $26200 highest and $17500 lowest target. $240.79’s average target is -2.05% below currents $245.84 stock price. Edwards Lifesciences Corporation Common Stock had 22 analyst reports since July 16, 2019 according to SRatingsIntel. The firm has “Hold” rating by Deutsche Bank given on Thursday, October 24. Credit Suisse maintained it with “Outperform” rating and $26100 target in Monday, October 14 report. The stock has “Overweight” rating by Morgan Stanley on Tuesday, July 16. Bank of America maintained the stock with “Buy” rating in Thursday, October 24 report. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, October 24 report. The stock of Edwards Lifesciences Corporation (NYSE:EW) has “Outperform” rating given on Friday, September 6 by Wells Fargo. As per Monday, October 14, the company rating was maintained by Raymond James. The firm has “Overweight” rating by Morgan Stanley given on Wednesday, July 24. UBS maintained it with “Neutral” rating and $23000 target in Wednesday, October 16 report. The company was maintained on Thursday, October 24 by Wells Fargo.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.